XBiotech Inc.

DB:4XB Stock Report

Market Cap: €133.7m

XBiotech Management

Management criteria checks 2/4

XBiotech's CEO is John Simard, appointed in Mar 2005, has a tenure of 19.75 years. total yearly compensation is $5.56M, comprised of 19.2% salary and 80.8% bonuses, including company stock and options. directly owns 12.54% of the company’s shares, worth €16.77M. The average tenure of the management team and the board of directors is 7.1 years and 7.7 years respectively.

Key information

John Simard

Chief executive officer

US$5.6m

Total compensation

CEO salary percentage19.2%
CEO tenure19.8yrs
CEO ownership12.5%
Management average tenure7.1yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Simard's remuneration changed compared to XBiotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$33m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$6mUS$1m

-US$25m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$5mUS$881k

-US$33m

Sep 30 2022n/an/a

-US$36m

Jun 30 2022n/an/a

-US$27m

Mar 31 2022n/an/a

-US$20m

Dec 31 2021US$8mUS$777k

-US$17m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$3mUS$684k

-US$11m

Sep 30 2020n/an/a

US$677m

Jun 30 2020n/an/a

US$673m

Mar 31 2020n/an/a

US$674m

Dec 31 2019US$11mUS$591k

US$669m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$1mUS$585k

-US$21m

Sep 30 2018n/an/a

-US$22m

Jun 30 2018n/an/a

-US$23m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$702kUS$566k

-US$33m

Compensation vs Market: John's total compensation ($USD5.56M) is above average for companies of similar size in the German market ($USD468.04K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Simard (62 yo)

19.8yrs

Tenure

US$5,556,481

Compensation

Mr. John Simard is the Founder of XBiotech, Inc. and serves as its Chairman and has been its Chief Executive Officer and President since March 2005. Mr. Simard serves as the Chairman, Chief Executive Offic...

Leadership Team

NamePositionTenureCompensationOwnership
John Simard
Founder19.8yrsUS$5.56m12.54%
€ 16.8m
Angela Hu
Director of Finance1.8yrsUS$279.29k0.084%
€ 111.8k
Sushma Shivaswamy
Chief Scientific Officer7.1yrsUS$720.50k0%
€ 0

7.1yrs

Average Tenure

46yo

Average Age

Experienced Management: 4XB's management team is seasoned and experienced (7.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Simard
Founder19.8yrsUS$5.56m12.54%
€ 16.8m
W. McKenzie
Independent Director15.8yrsUS$190.94k8.65%
€ 11.6m
Donald MacAdam
Independent Director6.8yrsUS$187.94k0.033%
€ 43.9k
Peter Libby
Member of Scientific Advisory Board & Independent Director6.3yrsUS$163.94k0.082%
€ 109.7k
Alice Gottlieb
Member of Scientific Advisory Board6.3yrsno datano data
Alexander Knuth
Member of Scientific Advisory Board7.7yrsno datano data
Razelle Kurzrock
Member of Scientific Advisory Board7.7yrsno datano data
Andrew Hendifar
Member of Scientific Advisory Board7.7yrsno datano data
Jan-Paul Waldin
Lead Independent Director6.8yrsUS$196.94k0.66%
€ 878.3k
Evangelos Giamarellos-Bourboulis
Member of Scientific Advisory Boardno datano datano data
Mark Rupp
Member of Scientific Advisory Boardno datano datano data

7.7yrs

Average Tenure

75yo

Average Age

Experienced Board: 4XB's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 06:08
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

XBiotech Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaNOBLE Capital Markets, Inc.
Joseph CatanzaroPiper Sandler Companies